

Director: Mrs D Pritchard  
Manager: Miss A De'Ath

Tel: +44 (0) 1443 622185  
Email: [ukneqashandi@wales.nhs.uk](mailto:ukneqashandi@wales.nhs.uk)  
Web: [www.ukneqashandi.org.uk](http://www.ukneqashandi.org.uk)

UK NEQAS for H&I  
Welsh Blood Service  
Ely Valley Road  
Talbot Green  
Pontyclun  
CF72 9WB

## UK NEQAS for H&I - Performance Report – Issued 15-Jan-2026

Page 1 of 2

Period covered: April 2025 – March 2026

**Laboratory Name:** UCK GDANSK  
Uniwersyteckie Centrum Kliniczne  
Immunologii i Transplantologii Klinicznej  
Bud. CMN poziom 0  
Smoluchowskiego 17  
GDANSK  
80-210  
Poland

This performance report must be evaluated in conjunction with the individual performance reports issued throughout the year, and alongside the assessment and performance information in the UK NEQAS for H&I 2025 Participants Manual, available on our website. Please note that the “% correct” figures have been rounding up to the nearest whole number.

### Scheme 2B - Crossmatching by Flow Cytometry

Laboratories are considered Satisfactory Performers if they make 85% or more of flow cytometry crossmatch assignments in agreement with the consensus findings. T cell & B cell results are considered independently, however all registered categories results must be in agreement with the consensus result for acceptable performance.

#### Cells Tested:

T cells: YES                      B cells: YES

### Scheme 2B - Crossmatching by Flow Cytometry – T cells

2B 01-10/2025:                      40 crossmatch combinations received  
40 T cell crossmatch combinations tested  
38 T cell crossmatch combinations assessed  
38 T cell crossmatch combinations assigned correctly  
100% T cell crossmatch combinations assigned correctly

**PERFORMANCE:**                      **SATISFACTORY PERFORMANCE**

### Scheme 2B - Crossmatching by Flow Cytometry – B cells

2B 01-10/2025:                      40 crossmatch combinations received  
40 B cell crossmatch combinations tested  
35 B cell crossmatch combinations assessed  
35 B cell crossmatch combinations assigned correctly  
100% B cell crossmatch combinations assigned correctly

**PERFORMANCE:**                      **SATISFACTORY PERFORMANCE**

Period covered: April 2025 – March 2026

Laboratory Name: UCK GDANSK

### **Scheme 8 – HLA Genotyping for Coeliac and Other HLA Associated Diseases**

Laboratories are considered Satisfactory Performers if they make 100% of reports in agreement with the reference genotypes in a year.

#### **Diseases Tested:**

Coeliac Disease:	YES	Behcet's Disease:	NO
Narcolepsy:	NO	Rheumatoid Arthritis:	NO
Actinic Prurigo:	NO	Diabetes:	NO
Birdshot Retinopathy:	NO	Psoriasis:	NO

### **Scheme 8 – HLA Genotyping for Coeliac Disease:**

8 01-10/2025: 10 samples received  
10 samples assessed  
10 correct genotypes assigned

ASSESSMENT: 100% correct genotype assignments

PERFORMANCE: **SATISFACTORY PERFORMANCE**

### **Scheme 9 – KIR Genotyping Scheme**

Laboratories are considered Satisfactory Performers if they make 90% or more full KIR genotypes in agreement with the consensus genotypes in a year.

#### **Loci Tested:**

2DL1: YES	2DL5: YES	3DS1: YES	2DS4: YES
2DL2: YES	3DL1: YES	2DS1: YES	2DS5: YES
2DL3: YES	3DL2: YES	2DS2: YES	2DP1: YES
2DL4: YES	3DL3: YES	2DS3: YES	3DP1: YES

9 01-10/2025: 10 samples received  
10 samples assessed  
10 correct genotypes assigned

ASSESSMENT: 100% correct genotype assignments

PERFORMANCE: **SATISFACTORY PERFORMANCE**

~~~~~ **END OF REPORT** ~~~~~

Report issued by: Amy De'Ath